Merck, S7067-25MG, SB 202190

General description
SB202190 aids in enhancing the self-renewal ability of neural stem cells fromNPC1-deficient mice.
Application
SB 202190 was used to inhibit p38 activation in MCF7 cells⁵, mouse macrophages⁶ and HepG2 cells.⁷
SB 202190 has been used: to investigate the role of p38mitogen-activated protein kinase (MAPK) signaling in establishment of reovirus infection
as a p38α inhibitor in in vivo studies to study its impact on the development or progression of adenocarcinoma in the colon mucosa tissues of APC Miⁿ/⁺mice.
as a component of basic BC medium to culture basal progenitor cells.
as a component of normal endometrium and endometrial tumor media for organoid culture.

Biochem/physiol Actions
SB 202190 is a highly selective, potent and cell permeable inhibitor of p38 MAP kinase. SB 202190 binds within the ATP pocket of the active kinase (Kd = 38 nM, as measured in recombinant human p38), and selectively inhibits the p38α and β isoforms.
Features and Benefits
This compound is featured on the MAPKs page of the Handbook of Receptor Classification and Signal Transduction. To browse other handbook pages, click here.
This compound was developed by GlaxoSmithKline. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.
Legal Information
Sold for research purposes under agreement from Glaxo­Smith­Kline